ICYMI: Korea's largest trading company POSCO International and LG CNS selected Injective as their blockchain partner to power their first onchain trade finance pilot. The pilot successfully ran on $INJ using trade receivables generated through real commerce,

Korea's largest trading company POSCO International and LG CNS selected Injective as their blockchain partner to power their first onchain trade finance pilot. The pilot successfully completed a transaction using trade receivables generated through real commercial activity, showcasing: ▸ Programmable tokenized receivables ▸ Compliance controls and regulated issuance rails ▸ AI-assisted trade document review ▸ Institutional-grade onchain infrastructure Trade finance supports more than $5 trillion in annual financing. This pilot demonstrates how Injective's purpose-built infrastructure stack for finance can be utilized to modernize one of the world’s largest financial markets via regulated rails while still sustaining lightning fast speeds, the lowest fees and novel new RWA issuance routes. Powered by $INJ

Global trade moved onchain this week powered by $INJ POSCO International and LG CNS selected Injective for their first blockchain trade finance PoC, then completed a transaction backed by receivables from real commercial activity. Below are some of the top developments that happened on Injective from the past week ⤵️ 🟪 POSCO International and LG CNS selected Injective for their first onchain trade finance pilot and completed a transaction using receivables from real commercial activity. 🟪 The latest Injective mainnet upgrade is officially live with new interoperability routes, lower block times, optimized $INJ staking, and new onchain revenue rails. 🟪 Native USDC deposits and withdrawals are officially live on @krakenfx, letting users move Circle's $USDC directly between Kraken and Injective. 🟪 The Injective AI Agent SDK is officially live, letting builders install the stack with one command and move from docs research to chain queries and onchain execution inside one workflow. 📊 Key Stats 🟪 Injective block times now run below 0.6 seconds on mainnet after the latest upgrade. 🟪 @HelixMarkets recorded $184 million in 7 day volume and reached $79 billion in cumulative volume across its onchain markets. 🌐 Ecosystem News 🟪 The official @Bitwise validator is live, giving anyone a direct path to stake $INJ through Injective Hub or a Ledger wallet. 🟪 The research team at @FourPillarsFP is now live as an institutional validator on Injective with 99.9%+ uptime. 🟪 The Injective Nova Program Demo Day with @Microsoft closed with 10 finalists pitching AI and Web3 projects. Build the New Internet Economy with us 🥷

Injective in the past few weeks: ✅Official SEC Transfer Agent Registration ✅Korea's largest trading company POSCO AND LG CNS launch tokenization pilot with Injective ✅$INJ listed on @RobinhoodCrypto ✅MiCA Whitepaper in the EU ✅@krakenfx integrates Injective USDC ✅@coinbase integrates native $INJ ✅Injective Summit with U.S. Senate, major financial institutions and members of Congress ✅Linux x402 Foundation invites Injective as a core member ✅@Bitwise becomes an Injective validator ✅Injective crosses 3 billion transactions ✅Brand new Injective website ✅AI Agent SDK release on Injective Much more L O A D I N G

Injective now has SEC Transfer Agent Registration ✅ MiCA Whitepaper in the EU ✅ Injective Mint Alpha for Tokenizing Assets ✅ LG CNS and Korea’s largest trading firm POSCO selecting Injective for its tokenization pilot ✅ Institutional-grade RWAs are here on $INJ

Most of the conversation around financial agents has focused on trading. POSCO International and LG CNS are showing another use. They are testing a trade finance workflow where AI agents handle the repetitive work of reviewing Letters of Credit and supporting documents. The commercial receivables are issued on Injective as permissioned assets with compliance rules embedded. That gives everyone involved a shared record and cuts down the manual reconciliation that slows trade finance today.

The biggest $INJ story of the year is also the most boring one Korea's largest trading company put real invoices onchain and crypto twitter scrolled straight past it 🥷 POSCO International, $22.2B in revenue, ran a live trade finance pilot with LG CNS on Injective Not a testnet demo, real commercial receivables : ∟ Invoices issued as permissioned tokens, the compliance rules travel with the asset across borders ∟ AI reviewing the Letters of Credit and the trade documents ∟ Live data pulled from 80+ overseas branches ∟ Settlement onchain instead of a multi day reconciliation between banks ∟ Framework locked in H2 2026, then phased rollout across every subsidiary → Trade finance moves more than $5 trillion a year and most of it still runs on paper and email → The first real piece of it just settled on the ninja chain They picked @injective because the compliance lives inside the protocol, not bolted on after in a contract

📰 #BitbaseDailyNews｜August# 11 Bitcoin spot ETFs saw a net outflow of $145M yesterday, led by BlackRock’s IBIT ($53.56M outflow). Meanwhile, South Korea’s LG CNS is set to launch a stablecoin blockchain service in September, and Bitdeer reported a 47% YoY Q2 revenue surge ($228.8M). On the market front,$DOS rockets by +102.16% to lead today’s top gainers! 📊 24H Market Trends: 🟡 Fear & Greed: 37 (Fear) ｜ 24H Vol: $54.07 B 📈 Bitbase TOP GAINERS: $DOS (+102.16%), $TOAD (+45.71%), $STONK (+27.02%) ⚖️ Long/Short: $BTC (Long 49.06%) ｜ $ETH (Long 49.31%) 💬 With spot ETFs seeing a brief pause and Fear & Greed sliding to 37, do you view this as a prime buy-the-dip window or are we due for more consolidation? Drop your thoughts below! 👇

📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $QURE uniQure Reports Updated Huntington’s Gene Therapy Data Through 48 Months 👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ➤ 𝗨𝗻𝗶𝗤𝘂𝗿𝗲 reports updated Phase I/II data for 𝗶𝗳𝗲𝘇𝘂𝗻𝘁𝗶𝗿𝗴𝗲𝗻𝗲 𝗶𝗻𝗶𝗹𝗽𝗮𝗿𝘃𝗼𝘃𝗲𝗰. ➤ At 36 months, high-dose patients showed 𝟴𝟬% slower cUHDRS progression. ➤ 36-month TFC progression slowed 𝟲𝟳% versus matched external controls. ➤ At 48 months, cUHDRS slowing was 𝟰𝟰% and not statistically significant. ➤ 48-month TFC showed 𝟲𝟭% slowing with nominal 𝗽=𝟬.𝟬𝟬𝟴. ➤ Sensitivity analysis showed 𝟱𝟰% cUHDRS and 𝟲𝟴% TFC slowing. ➤ Missing external-control data reached 𝟱𝟯% at the 48-month timepoint. ➤ Five high-dose patients, or 𝟭𝟳%, experienced treatment-related serious CNS inflammation. ➤ 𝗨𝗻𝗶𝗤𝘂𝗿𝗲 submitted an accelerated-approval 𝗕𝗟𝗔 to the FDA. ➤ FDA previously accepted 36-month data as the submission's primary basis. 👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: ➤ Longer-term data provide additional evidence on potential durability in 𝗛𝘂𝗻𝘁𝗶𝗻𝗴𝘁𝗼𝗻’𝘀 disease. ➤ Significant 𝗧𝗙𝗖 slowing at 48 months supports continued functional-effect evaluation. ➤ However, 48-month 𝗰𝗨𝗛𝗗𝗥𝗦 results introduce uncertainty by missing statistical significance. ➤ High missing-control data complicates interpretation of the 𝟰𝟴-𝗺𝗼𝗻𝘁𝗵 comparison. ➤ FDA review of the 𝗕𝗟𝗔 is the key regulatory catalyst ahead.